Form 4: Celularity Executive Reports RSU Vesting and Tax Sale

Stephen Brigido, President of Functional Regeneration at Celularity Inc., reported the vesting of restricted stock units and a subsequent tax-related share disposition.

Summary

• Stephen Brigido, President of Functional Regeneration, acquired 821 shares of Class A Common Stock through the vesting of restricted stock units (RSUs).
• A total of 268 shares were withheld by the company to satisfy tax obligations associated with the vesting event.
• Following these transactions, the reporting person holds 9,474 shares of Class A Common Stock.
• The transactions occurred on April 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing related to executive compensation, having no material impact on the company's financial position.

Positives

• The transaction reflects the fulfillment of long-term incentive compensation plans for key management personnel.

Negatives

• The company withheld 268 shares for tax purposes, which is a standard administrative procedure but reduces the net share gain for the executive.

Risks

• No specific operational or financial risks are disclosed in this ownership filing.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive equity compensation and does not signal a change in corporate strategy or market outlook.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices regarding the vesting of equity-based compensation for executives.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Key Dates

Keywords

Celularity, CELU, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation